Relugolix(MYFEMBREE)
Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection
Manufacturer:
Sumitomo Pharma
Validity period:
24 months
Reminder: The outer packaging is for reference only, please purchase and use under the guidance of
a
pharmacist. For read by medical and pharmaceutical professionals only.
MYFEMBREE(Relugolix) Instructions:Uses,Dosage, Side Effects
MYFEMBREE is a medication used to manage conditions such as heavy menstrual bleeding caused by uterine fibroids and moderate to severe pain associated with endometriosis in premenopausal women. It combines three active ingredients: relugolix, a GnRH receptor antagonist; estradiol, an estrogen; and norethindrone acetate, a progestin.
The medication is available as a fixed-dose combination tablet, and it is crucial to follow the prescribed dosage and administration instructions, including excluding pregnancy before starting treatment. The use of MYFEMBREE can cause side effects, so monitoring and proper medical advice are important throughout treatment.
Generic name
Relugolix(MYFEMBREE)
Alternative Names
MYFEMBREE
Indications
Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women.
Management of moderate to severe pain associated with endometriosis in premenopausal women.
Therapeutic Target
Gonadotropin-releasing hormone (GnRH) receptors, estrogen receptors, and progesterone receptors
Active Ingredients
Relugolix 40 mg (GnRH receptor antagonist) Estradiol 1 mg (estrogen) Norethindrone acetate 0.5 mg (progestin)
specifications
40mg,1mg,1.5mg*28 tablets/bottle
Description
MYFEMBREE is a fixed-dose combination tablet containing relugolix (40 mg), a GnRH receptor antagonist, estradiol (1 mg), an estrogen, and norethindrone acetate (0.5 mg), a progestin. The tablets are light yellow to yellow, round, film-coated, and debossed with "MVT" on one side and "415" on the other side.
Dosage and Administration
One tablet orally once daily at approximately the same time, with or without food;Start as early as possible after the onset of menses but no later than seven days after menses has started;Recommended total duration of treatment is 24 months.
RELATED ARTICLES
Dosage and Administration of Relugolix
Relugolix is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, often formulated as a fixed-dose...
Wednesday, December 3rd, 2025, 09:30
What Are the Indications of Relugolix?
Relugolix is an oral medication, often used in combination with estradiol and norethindrone acetate to form the...
Wednesday, December 3rd, 2025, 09:22
Side Effects of Relugolix (Orgovyx)
Relugolix (Orgovyx) is an oral gonadotropin-releasing hormone receptor antagonist indicated for the treatment of...
Wednesday, November 26th, 2025, 10:55
Contact Us
Mailbox:Info@Lucius.La
Ucius Pharmaceuticals (Lao) Co.,Ltd All Rights Reserved
